
Revolutionizing Veterinary Oncology: Insights from the 2025 Fetch Charlotte Conference
At the forefront of recent advancements in veterinary oncology is the work of Philip Bergman, DVM, MS, PhD, DACVIM (Oncology), who introduced groundbreaking developments during his keynote address at the 2025 Fetch Charlotte conference in North Carolina. The conversation around veterinary care is shifting, especially with the introduction of novel treatment options like a canine melanoma vaccine and emerging pharmacogenetic testing.
Tackling Nausea and Vomiting in Veterinary Patients
A significant issue among cancer patients—both human and animal—is managing nausea and vomiting. Many pets undergoing treatments, be it surgery or chemotherapy, encounter these distressing side effects, complicating their overall care. Cerenia, a novel veterinarian-specific drug developed to combat nausea in dogs and cats, shows promise by providing effective relief against vomiting caused by various treatments. This NK1 receptor antagonist is being widely recognized for its superior efficacy, similar to a human counterpart, Emend, highlighting a pivotal advancement in ensuring a better quality of life for animal oncology patients.
The Melanoma Vaccine: Breaking New Ground in Cancer Treatment
Certainly, one of the most notable innovations discussed by Bergman was the development of a vaccine for canine malignant melanoma, which is alarmingly prevalent and aggressive in dogs. Traditionally, treatment options have been limited and often ineffective. The Bioject delivery system employed for the melanoma vaccine enhances immune response, making it a promising option compared to former techniques. The vaccine targets tyrosinase, an enzyme critical to melanin production, and is delivered via a needle-free method, increasing its potential effectiveness. This progress could radically alter the treatment landscape for melanoma, providing hope for improved outcomes in canine patients.
Prioritizing Genetic Testing in Veterinary Medicine
Compounding these advancements, the conversation highlighted the importance of pharmacogenetic testing, especially concerning the discovery of the MDR1 mutation, frequently dubbed ‘white feet don’t treat’ due to its association with specific breeds. As Bergman indicated, early genetic testing could avert serious issues during treatment, essentially leading to more personalized and safer care practices, emphasizing preventive medicine. This capability to identify at-risk breeds from a young age could significantly enhance treatment outcomes and safety.
With these dynamic advances, veterinary clinics must consider incorporating these innovative therapies and genetic testing into their service offerings not only to stay up-to-date with industry standards but also to provide optimal care for their patients. As veterinary medicine continues to evolve, the integration of cutting-edge research and clinical advancements will be essential for practitioners aiming to improve patient outcomes and enhance their operational efficiency.
Conclusion: Embrace Change for Better Veterinary Care
To stay competitive in today’s rapidly evolving veterinary landscape, clinic owners and practitioners are encouraged to embrace these advancements. By focusing on cutting-edge therapies and early genetic testing, practices can enhance their service offerings, ultimately leading to better care for their patients and increased client loyalty.
Write A Comment